Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2226 - 2250 of 15111 in total
Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of...
Approved
Investigational
Vet approved
Matched Description: … proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic ... Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and ... children and may also be considered in the treatment of illnesses caused by other protozoa or helminths …
Matched Categories: … Antiparasitic Products, Insecticides and Repellents …
Tasonermin is recombinant soluble form tumor necrosis factor α produced via Escherichia coli cell culture. It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft...
Approved
Matched Description: … Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
Approved
Matched Description: … Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for …
Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and...
Approved
Investigational
Matched Description: … It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands ... , a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression ... Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Spesolimab is an interleukin-36 (IL-36) receptor antagonist. It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares. Spesolimab...
Approved
Investigational
Matched Description: … works by inhibiting the inflammatory signaling pathway of IL-36,[L43090] which is often overexpressed and ... Committee for Medicinal Products for Human Use (CHMP) to be granted marketing authorization in October 2022 and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.
Approved
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …
A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.
Approved
Matched Description: … A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal...
Approved
Investigational
Withdrawn
Matched Description: … to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and ... was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and...
Approved
Investigational
Matched Description: … agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and ... [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for ... use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of...
Approved
Investigational
Matched Description: … promotes tumor cell lysis and apoptosis. ... monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and ... blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in combination with DB13941 as the product Eurartesim. Artemisinin combination therapy is highly effective against malaria and...
Approved
Experimental
Investigational
Matched Description: … Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated ... Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World …
Matched Categories: … Artemisinin and derivatives ... artenimol and piperaquine ... Antiparasitic Products, Insecticides and Repellents …
Dihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).
Approved
Experimental
Matched Description: … is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and
Matched Categories: … dihydralazine and diuretics ... Hydrazinophthalazine Derivatives and Diuretics ... dihydralazine and diuretics, combinations with other drugs …
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to brentuximab vedotin, another...
Approved
Investigational
Matched Description: … clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and ... Seattle Genetics [A188868] and it was first approved for use in the United States in December 2019 under ... [L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.
Approved
Matched Description: … A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical …
Matched Categories: … Antiseptics and Disinfectants …
Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein which serves as a driver of CML proliferation in most patients with the disease....
Approved
Investigational
Matched Description: … those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those ... Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into ... in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384,...
Approved
Investigational
Matched Description: … treatment for HGPS and other related progeroid laminopathies. ... [A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed ... [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D).[A241480,A241045,A241475,L44091] T1D is an autoimmune condition in which T cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and reliance on exogenous insulin. Anti-CD3 therapy...
Approved
Investigational
Matched Description: … L44091] Fc-receptors can bind to the "tail-end" anti-CD3 antibodies in an antigen-non-specific manner and ... cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and ... mechanism of action of teplizumab has not been fully elucidated, it may involve partial agonistic signaling and
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate. Trials...
Approved
Investigational
Matched Description: … [L39140] It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 ( …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Anethole trithione (ATT) appears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia [A27165, A32618, A32620, A32621], to demonstrating an ability to inhibit carcinogenesis by increasing the activity of electrophile detoxification enzymes , and even being used as an adjunctive therapy for cholecystitis,...
Approved
Experimental
Matched Description: … hepatitis [L2388] and is marketed in certain countries like France, Germany, and China [A32614]. ... inhibit carcinogenesis by increasing the activity of electrophile detoxification enzymes [A32619], and ... even being used as an adjunctive therapy for cholecystitis, gallstone, indigestion, and acute/chronic …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Eftrenonacog alfa is a long-acting recombinant fusion protein used in the treatment of hemophilia B. It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H)...
Approved
Investigational
Matched Description: … It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. ... Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. ... blood disorder with an incidence of approximately once every 30,000 male births in all populations and
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control...
Approved
Investigational
Matched Description: … The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus. ... During the process, viruses are deactivated, and in the final steps, solvents used in the preparation ... According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
Approved
Vet approved
Displaying drugs 2226 - 2250 of 15111 in total